Levita Magnetics logo

Levita Magnetics

Levita Magnetics is a Mountain View surgical robotics company whose MARS platform uses magnets and a robotic arm to assist minimally invasive procedures. It has FDA clearance for Magnetic-Assisted Robotic Surgery and has highlighted AI-guided camera cases in Chile.1,2,1

Robotics Reviewed Editorial TeamUpdated November 5, 2026levita.com

Our take

Levita's magnetic approach is a narrower surgical robotics bet than full multiport systems from Intuitive-scale peers, which can be an advantage in high-volume laparoscopic cases.2,1

Commercial evidence is still earlier than large soft-tissue robot makers, so deployment proof matters more than brand awareness today.3

Scores by criterion

Levita Magnetics scores out of 10
Pricing transparency3.0
Product maturity7.0
Deployment evidence6.0
Company durability6.0
Ease of integration5.5
Overall score (average of the five)5.5

Each criterion is defined on our methodology page.

Who uses Levita and what it's for

Hospitals and ambulatory surgery centers performing high-volume laparoscopic cases such as gallbladder surgery are the core buyers.2,1

Latin American and US sites are part of Levita's expansion, including a Miami hub.4

History

Dr. Alberto Rodriguez-Navarro founded Levita Magnetics and serves as CEO. The company is based in Mountain View, California.3,1

Levita raised $26 million in a Series C in 2022 to advance MARS and has raised more than $50 million overall, with a further growth round reported in 2026.3,6

MARS magnetic surgery

MARS combines magnetic surgical tools with robotic assistance so surgeons can reduce incisions in laparoscopic procedures.1,2

In 2023 the company won FDA clearance for the MARS system. It later reported AI-guided autonomous camera assistance in a landmark case in Santiago, Chile.2,1

Pricing

Levita does not publish capital or per-procedure prices on its public site. Hospital buyers negotiate through the company's commercial team.1

Competitive landscape

Which of these companies scores best, and who is each one built for?Hover over or tap a logo for details.
Top rated, for patients and clinicsTop rated, for large hospitalsLower score, for patients and clinicsLower score, for large hospitals45678910Review Score← Patients and clinicsLarge hospital systems →Who it's built for5.55.86.16.56.5
Levita Magnetics and its competitors
CompanyProductPricing modelDeployment footprintWhere Levita wins or loses
Levita MagneticsMARS magnetic-assisted robotic surgery platform1Quote-only capital and procedure pricing1FDA-cleared MARS system with US and Latin America sites2Magnetic-assisted laparoscopic robotics rather than a full multiport console
Moon SurgicalMaestro bedside assistant with ScoPilot AI camera control15Not published8FDA cleared in 2024; dataset of more than 3,000 procedures7,15Moon Surgical wins on soft-tissue assistance with Maestro. Levita wins on magnetic port reduction.
Distalmotion (DEXTER)DEXTER soft-tissue surgical robot with a small, mobile footprint10Not published10Almost 3,000 patients treated; three US clearances10Distalmotion wins on Dexter as a broader soft-tissue robot. Levita wins on magnet-focused MIS workflows.
CMR Surgical (Versius)Versius Plus modular surgical robot11Not published1145,000 cases worldwide; FDA 510(k) for gallbladder removal11CMR wins on Versius multiport robotics. Levita wins on a narrower magnetic approach.
StereotaxisGenesis robotic magnetic navigation and MAGiC catheters14Capital system sale, plus per-procedure disposables, service, and software updates12More than 100,000 patients treated at over 100 hospitals13Stereotaxis wins on magnetic cardiac ablation. Levita wins on laparoscopic general surgery magnets.

Limits

Pricing is not public.1

Indication coverage and hospital credentials still limit how widely MARS is used versus general-purpose surgical robots.2

Revenue is not disclosed. Datanyze estimates about $11.3 million for 2025. This is an estimate, not a reported figure.5

What customers say

Where it helps

High-volume laparoscopic programs that want fewer ports may evaluate MARS before a full multiport robot.2

Systems already studying magnetic surgery tools have a shorter path to adoption.1

Where it falls short

Hospitals wanting a broader soft-tissue robot should look at Distalmotion or Moon Surgical's assistant-style systems.

Leadership

Sources